Alerts will be sent to your verified email
Verify Email
ASPIRA
|
Aspira Pathlab&Diagn
|
Invicta Diagnostic
|
Nephro Care India
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-3.47 % | 36.05 % | 143.87 % |
|
5yr average Equity Multiplier
|
1.42 | 1.54 | 18.06 |
|
5yr Average Asset Turnover Ratio
|
1.0 | 1.21 | 1.28 |
|
5yr Avg Net Profit Margin
|
-3.89 % | 20.01 % | 8.51 % |
|
Price to Book
|
5.34 | 6.7 | 3.5 |
|
P/E
|
27.08 | 20.12 | 51.31 |
|
5yr Avg Cash Conversion Cycle
|
-26.26 Days | 3155.19 Days | -60.13 Days |
|
Inventory Days
|
10.15 Days | 7.26 Days | 6.87 Days |
|
Days Receivable
|
38.11 Days | 14.01 Days | 13.4 Days |
|
Days Payable
|
81.06 Days | -2240.05 Days | 75.6 Days |
|
5yr Average Interest Coverage Ratio
|
0.45 | 40.66 | 32.99 |
|
5yr Avg ROCE
|
-0.04 % | 37.62 % | 25.8 % |
|
5yr Avg Operating Profit Margin
|
6.02 % | 37.67 % | 13.74 % |
|
5 yr average Debt to Equity
|
0.1 | 0.32 | 10.46 |
|
5yr CAGR Net Profit
|
n/a | 82.73 % | 109.59 % |
|
5yr Average Return on Assets
|
-2.37 % | 23.37 % | 12.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
18.39 % | n/a | 61.47 % |
|
Share Pledged by Promoters
|
0.0 | n/a | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-16.16 % | n/a | 0.09 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | n/a | 0.0 |
|
Aspira Pathlab&Diagn
|
Invicta Diagnostic
|
Nephro Care India
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|